The phase Ib/II trial, which followed 33 patients for a median of 21.5 months, highlights how targeting the FAK-YAP signaling pathway can overcome the adaptive resistance that often renders KRAS G12C monotherapies less effective. Among the participants, 27 achieved a response, with the median duration of response currently not reached. The regimen notably extended median progression-free survival to 22.3 months, with a median overall survival of 27.8 months.

Dr. Zaiqi Wang, CEO of InxMed, noted that the combination blocks the adaptive resistance pathways typically triggered by KRAS inhibition. Safety data remains encouraging; while all patients experienced treatment-emergent adverse events, most were mild, and no treatment-related deaths were reported. This chemotherapy-free, all-oral approach is now being validated in a randomized phase III confirmatory trial, aiming to establish a new standard of care for the 12-14% of non-small cell lung cancer cases involving the KRAS G12C mutation.